leo: resolve merge conflict — apply Aon GLP-1 enrichments to post-restructure main
- What: Cherry-picked Aon employer cost savings enrichments, resolved conflicts with WHO GLP-1 enrichments (both kept) - Why: Epimetheus archive restructure + parallel WHO enrichment merge caused conflicts Pentagon-Agent: Leo <A3DC172B-F0A4-4408-9E3B-CF842616AAE1>
This commit is contained in:
parent
25a2bcf36e
commit
e535a86a28
6 changed files with 68 additions and 1 deletions
|
|
@ -89,6 +89,11 @@ BALANCE Model's dual payment mechanism (capitation adjustment + reinsurance) plu
|
|||
|
||||
WHO's conditional recommendation structure and behavioral therapy requirement suggest the 'chronic use model' framing may be incomplete. The guideline establishes medication-plus-behavioral-therapy as the standard, not medication alone, which may have different economics than the pure pharmaceutical model. WHO also announced it will develop 'an evidence-based prioritization framework to identify which adults with obesity should be prioritized for GLP-1 treatment'—implying targeted use rather than universal chronic treatment.
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18*
|
||||
|
||||
Aon's 192K patient analysis shows medical costs grow only 2% for GLP-1 users after 12 months versus 6% for non-users, with diabetes patients showing 6-9 percentage points lower cost growth at 30 months depending on adherence. This suggests the 'inflationary through 2035' claim may be payment-model-dependent rather than universally true—capitated long-term risk-bearers may see net savings while FFS short-term payers see inflation.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -77,6 +77,11 @@ BALANCE Model's manufacturer-funded lifestyle support requirement directly addre
|
|||
|
||||
WHO's conditional recommendation requiring behavioral therapy combination provides international regulatory support for adherence interventions. The guideline explicitly states GLP-1s should be 'combined with intensive behavioral therapy to maximize and sustain benefits'—directly addressing the persistence problem by making behavioral support the standard of care rather than an optional add-on.
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18*
|
||||
|
||||
Aon data shows adherence is the binding variable for cost-effectiveness: the 80%+ adherent cohort shows 9 percentage points lower cost growth for diabetes and 7 points lower for weight loss, versus 6 and 3 points for the overall population. This means the economic case requires not just persistence but high adherence, making the 15% two-year persistence rate even more problematic for chronic use economics.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -43,6 +43,12 @@ The source does not provide granular income-stratified discontinuation rates, so
|
|||
|
||||
The Trump Administration deal establishes a $50/month out-of-pocket maximum for Medicare beneficiaries, explicitly targeting affordability as a persistence barrier. The $245/month Medicare price (down from ~$1,350) combined with the OOP cap is designed to address the affordability-driven discontinuation pattern observed in lower-income populations.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18*
|
||||
|
||||
Aon data shows the 80%+ adherent cohort captures dramatically stronger cost offsets (9 points for diabetes vs 6 for overall population), meaning affordability barriers that reduce adherence don't just affect clinical outcomes—they eliminate the economic case for coverage, creating a self-reinforcing cycle where cost concerns prevent the adherence needed to justify the cost.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -40,6 +40,12 @@ FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major k
|
|||
|
||||
SELECT trial economic model shows $2,074 per-subject lifetime savings from avoided CKD, supporting the claim that kidney protection generates substantial cost savings. However, diabetes prevention ($14,431) generates even larger savings.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18*
|
||||
|
||||
Aon's real-world claims data confirms the temporal pattern of GLP-1 cost offsets: medical cost growth is 6 percentage points lower at 30 months for diabetes patients, with the savings materializing after the first 12 months when costs initially rise 23% versus 10% for non-users. This validates the kidney protection findings in a large commercial population.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -0,0 +1,32 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
{
|
||||
"filename": "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-women.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 2,
|
||||
"kept": 0,
|
||||
"fixed": 2,
|
||||
"rejected": 2,
|
||||
"fixes_applied": [
|
||||
"glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:set_created:2026-03-18",
|
||||
"glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-women.md:set_created:2026-03-18"
|
||||
],
|
||||
"rejections": [
|
||||
"glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:missing_attribution_extractor",
|
||||
"glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-women.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-18"
|
||||
}
|
||||
|
|
@ -7,9 +7,13 @@ date: 2026-01-13
|
|||
domain: health
|
||||
secondary_domains: [internet-finance]
|
||||
format: report
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [glp-1, employer-costs, cancer-risk, cardiovascular, cost-offset, real-world-evidence]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-18
|
||||
enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -49,3 +53,12 @@ WHY ARCHIVED: The temporal cost dynamics (costs up Y1, down Y2+) are the most im
|
|||
EXTRACTION HINT: Focus on the temporal cost curve and what it implies for different payment models. The cancer finding is separately important but preliminary.
|
||||
|
||||
flagged_for_rio: ["GLP-1 cost dynamics have direct implications for health investment thesis — long-term risk-bearers capture savings that short-term payers miss"]
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Aon analyzed 192,000+ GLP-1 users in U.S. commercial health claims data
|
||||
- First 12 months on Wegovy/Zepbound: medical costs rise 23% vs 10% for non-users
|
||||
- After 12 months: medical costs grow 2% vs 6% for non-users
|
||||
- Female GLP-1 users: ~50% lower ovarian cancer incidence, 14% lower breast cancer incidence
|
||||
- Adherent users (80%+): 47% MACE reduction for women, 26% for men
|
||||
- Study released January 13, 2026
|
||||
|
|
|
|||
Loading…
Reference in a new issue